Alambic Investment Management buys $2,532,816 stake in Medivation Inc (MDVN)

Medivation Inc (MDVN) : Alambic Investment Management scooped up 8,750 additional shares in Medivation Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 38,610 shares of Medivation Inc which is valued at $2,532,816.Medivation Inc makes up approximately 0.57% of Alambic Investment Management’s portfolio.

Other Hedge Funds, Including , Saturna Capital Corp reduced its stake in MDVN by selling 30,608 shares or 84.52% in the most recent quarter. The Hedge Fund company now holds 5,606 shares of MDVN which is valued at $367,754. Medivation Inc makes up approx 0.01% of Saturna Capital Corp’s portfolio. Advent Capital Management De sold out all of its stake in MDVN during the most recent quarter. The investment firm sold 6,000 shares of MDVN which is valued $379,500.Mizuho Trust Banking Ltd. boosted its stake in MDVN in the latest quarter, The investment management firm added 10,131 additional shares and now holds a total of 258,308 shares of Medivation Inc which is valued at $16,552,377. Medivation Inc makes up approx 0.05% of Mizuho Trust Banking Ltd.’s portfolio.Creative Planning reduced its stake in MDVN by selling 8,640 shares or 68.92% in the most recent quarter. The Hedge Fund company now holds 3,897 shares of MDVN which is valued at $239,938.

Medivation Inc closed down -0.72 points or -1.09% at $65.3 with 12,40,294 shares getting traded on Monday. Post opening the session at $66, the shares hit an intraday low of $65.03 and an intraday high of $66.01 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.26. The company had revenue of $206.20 million for the quarter, compared to analysts expectations of $209.92 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.

Many Wall Street Analysts have commented on Medivation Inc. Medivation Inc was Downgraded by JMP Securities to ” Mkt Perform” on Aug 10, 2016. Company shares were Reiterated by Wedbush on Jul 12, 2016 to “Outperform”, Firm has raised the Price Target to $ 66 from a previous price target of $63 .

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Leave a Reply

Medivation Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medivation Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.